CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors

Ya Ping Chen, Hui Ju Lin, Jiann Shiuh Chen, Ming Ying Tsai, Hsing Pang Hsieh, Jang Yang Chang, Nai Feng Chen, Kung Chao Chang, Wen Tsung Huang, Wu Chou Su, Shu Ting Yang, Wen Chang Chang, Liang Yi Hung, Tsai Yun Chen

研究成果: 雜誌貢獻文章同行評審

7 引文 斯高帕斯(Scopus)


Overexpression of Aurora kinases is largely observed in many cancers, including hematologic malignancies. In this study, we investigated the effects and molecular mechanisms of Aurora kinase inhibitors in acute lymphoblastic leukemia (ALL). Western blot analysis showed that both Aurora-A and Aurora-B are overexpressed in ALL cell lines and primary ALL cells. Both VE-465 and VX-680 effectively inhibited Aurora kinase activities in nine ALL cell lines, which exhibited different susceptibilities to the inhibitors. Cells sensitive to Aurora kinase inhibitors underwent apoptosis at an IC50 of-10-30 nM and displayed a phenotype of Aurora-A inhibition, whereas cells resistant to Aurora kinase inhibitors (with an IC50 more than 10 μM) accumulated polyploidy, which may have resulted from Aurora-B inhibition. Drug susceptibility of ALL cell lines was not correlated with the expression level or activation status of Aurora kinases. Interestingly, RS4;11 and MV4;11 cells, which contain the MLL-AF4 gene, were both sensitive to Aurora kinase-A inhibitors treatment. Complementary DNA (cDNA) microarray analysis suggested that CDKN1A might govern the drug responsiveness of ALL cell lines in a TP53-independent manner. Most importantly, primary ALL cells with MLL-AF4 and CDKN1A expression were sensitive to Aurora kinase inhibitors. Our study suggests CDKN1A could be a potential biomarker in determining the drug responsiveness of Aurora kinase inhibitors in ALL, particularly in MLL-AF4-positive patients. What's new? Aurora kinase overexpression is a phenomenon of many cancers, including hematologic malignancies, such as acute lymphoblastic leukemia (ALL). This study suggests that Aurora-A kinase inhibitors may have clinical utility in MLL-AF4-positive ALL and provides insight into the role of CDKN1A expression in governing ALL cell responsiveness to the drugs. CDKN1A acts in a TP53-independent manner and thereby serves as an indicator to determine drug responsiveness specifically in MLL-AF4-positive ALL cells.

頁(從 - 到)751-762
期刊International Journal of Cancer
出版狀態已發佈 - 8月 1 2014

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究


深入研究「CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors」主題。共同形成了獨特的指紋。